NRG Pallas

NRG Pallas is a global leader in the production of medical isotopes and a key provider of nuclear research services, headquartered in Petten, Netherlands. The organization operates the High Flux Reactor (HFR) and is spearheading the construction of the new PALLAS reactor to secure the long-term supply of life-saving isotopes. Their production portfolio includes Molybdenum-99, Lutetium-177, and Iodine-131, which are critical for the diagnosis and treatment of millions of cancer patients annually. In addition to manufacturing, NRG Pallas provides specialized R&D and consultancy services to the nuclear energy and healthcare sectors. The company plays a vital role in the radiopharmaceutical supply chain, supporting the development of next-generation targeted therapies.